Russell Anderson

Cooley advised EsoBiotec, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity, on its definitive agreement to be acquired by AstraZeneca (London Stock Exchange/Nasdaq Stockholm/Nasdaq: AZN) for up to $1 billion on a cash- and debt-free basis.

Cooley advised UiPath (NYSE: PATH), a leading enterprise automation and artificial intelligence (AI) software company, on its acquisition of Peak, an AI-native company based in Manchester, United Kingdom.

Cooley advised GeBBS Healthcare Solutions, a global provider of healthcare outsourcing solutions, and ChrysCapital, a top India-focused private equity firm, on the agreement for BPEA Private Equity Fund VIII (EQT Private Capital Asia) to acquire a controlling beneficial interest in GeBBS from ChrysCapital.

Cooley advised Adarga, an artificial intelligence-driven software leader, on its acquisition of J2X Solutions, a veteran-owned consulting company with a team that draws on decades of experience in the military and federal law enforcement to provide strategic risk intelligence.

Cooley advised Luna Innovations, a global leader in advanced fiber optic-based technology, on its $50 million investment from White Hat Capital Partners and its acquisition of Silixa.